The DONPAD-study - Treatment of dementia in patients with Parkinson's disease with donepezil

Journal of Neural Transmission, Supplement

Volumn , Issue 71, 2006, Pages 27-30

  Muller T ^a   Welnic, J ^a   Fuchs, G ^c   Baas, H ^d   Ebersbach, G ^e   Reichmann, H ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Parkinson Clinic   (Germany)

^d Hanau City Hospital   (Germany)

^e Movement Disorder Clinic   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DEMENTIA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTIVATION; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SHORT SYNDROME TEST; SLEEP DISORDER; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; MENTAL HEALTH; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; TIME;

AGED; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HUMANS; INDANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PIPERIDINES; TIME FACTORS;

EID: 34248597801     PISSN: 03036995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Aarsland D, Tandberg E, Larsen JP, Cummings JL (1996) Frequency of dementia in Parkinson disease. Arch Neurol 53: 538-542
2. Bohnen N, Kaufer D, Hendrickson R, Ivanco L, Moore R, DeKosky S (2004) Effects of donepezil on motor function in patients with Alzheimer disease. J Clin Psychopharmacol 24: 354-356
3. Di Lazzaro, V, Oliviero A, Pilato F, Saturno E, Dileone M, Marra C, Daniele A, Ghirlanda S, Gainotti G, Tonali PA (2004) Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease. J Neurol Neurosurg Psychiatry 75: 555-559
4. Edwards K, Therriault OJ, Gorman C (2004) Switching from donepezil or rivastigmine to galantamine in clinical practice. J Am Geriatr Soc 52: 1965
5. Emre M (2004) Dementia in Parkinson's disease: cause and treatment. Curr Opin Neurol 17: 399-404
6. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518
7. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD (2003) Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 108: 368-373
8. Goetz CG, LeWitt PA, Weidenman M (2003) Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord 18: 1455-1458
9. Hegerl U, Mergl R, Henkel V, Gallinat J, Kotter G, Muller-Siecheneder F, Pogarell O, Juckel G, Schroter A, Bahra R, Emir B, Laux G, Moller HJ (2003) Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol 23: 214-216
10. Heinze M, Andreae D, Grohmann R (2002) Rivastigmin and impaired motor function. Pharmacopsychiatry 35: 79-80
11. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
12. Koch HJ, Gurtler K, Szecsey A (2005) Correlation of Mini-Mental-State- Examination (MMSE), Syndrom-Kurztest (SKT) and Clock test (CT) scores in patients with cognitive impairment assessed by means of multiple regression and response surface analysis. Arch Gerontol Geriatr 40: 7-14
13. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19: 1-8
14. Overall JE, Schaltenbrand R (1992) The SKT neuropsychological test battery. J Geriatr Psychiatry Neurol 5: 220-227
15. Poirier J (2002) Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl: 6-19
16. Richard IH, Justus AW, Greig NH, Marshall F, Kurlan R (2002) Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine. Clin Neuropharmacol 25: 296-299
17. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E, Thai LJ, Corey-Bloom J (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54: 407-411
18. Wahle M, Haller S, Spiegel R (1996) Validation of the NOSGER (Nurse's Observation Scale for Geriatric Patients): reliability and validity of a caregiver rating instrument. Int Psychogeriatr 8: 525-547
19. Weinstock M (1999) Selectivity of cholinesterase inhibition - Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 12: 307-323
20. Werber EA, Rabey JM (2001) The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm 108: 1319-1325